Can mGluR5 antagonists be utilized to reduce beta-amyloid levels | 47889

Journal of Neurology & Neurophysiology

ISSN - 2155-9562

Can mGluR5 antagonists be utilized to reduce beta-amyloid levels in Alzheimer’s disease and other neurological disorders

International Conference and Exhibition on Neurology & Therapeutics

May 14-16, 2012 Embassy Suites Las Vegas, USA

Cara J. Westmark

Accepted Abstracts: J Neurol Neurophysiol

Abstract :

Yogesan Kanagasingam is the Research Director of the Australian e-Health Research Centre at CSIRO - and he is changing the way eye care is delivered around the world. He is an Adjunct Professor at the University of Notre Dame and a visiting scholar at the Harvard University. He has developed many award winning medical technologies that are used for prevention of blindness. One of his inventions, EyeScan device, is used in the Spacelab and another used in China for screening of diabetic patients in Guangdong province with 100 million people. His team was the first to demonstrate the relationship between the retina and Alzheimer?s disease, and also the first to develop ocular biomarkers for the non-invasive early detection of Alzheimer?s disease. An internationally recognized scholar, inventor and entrepreneur, Professor Yogesan has been the recipient of many awards including the Senior Fulbright Scholarship and the WA Inventor of the Year Mitsubishi Encouragement Award.